Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Arthritis Rheum. 2000 Oct;30(2 Suppl 1):11-8.

Intra-articular sodium hyaluronate in osteoarthritis of the knee.

Author information

1
Department of Rheumatology and Immunology, University of Miami School of Medicine, and the Geriatric Research, Education, and Clinical Center, VA Hospital, FL, USA. raltman@med.miami.edu

Abstract

OBJECTIVES:

Hyaluronan (HA) has recently been approved in the United States for management of pain in osteoarthritis (OA) of the knee and is the first biological available for use in OA. To better understand the therapeutic role of HA, this review focuses on comparative clinical trial data.

METHODS:

Literature reports of clinical trials comparing HA with placebo, nonsteroidal anti-inflammatory drugs, and intra-articular corticosteroids were reviewed. The pivotal US trial evaluating HA efficacy and safety was summarized.

RESULTS:

Over the past decade, 5 of 8 controlled clinical trials demonstrated HA was superior to placebo in relieving the pain of OA. A sixth trial showed improvement in a subset of older patients with more severe disease. Comparison of HA with corticosteroids showed equal pain relief in the first few weeks after therapy, with HA demonstrating more sustained benefit up to 60 days. In the recent US trial, HA was statistically superior to placebo and at least as effective as naproxen in providing analgesia. In all trials reporting adverse effects, the primary adverse effect with HA was pain at the injection site.

CONCLUSIONS:

HA appears effective in relieving the pain of OA of the knee and provides a relatively safe alternative for patients for whom conventional therapy has failed.

PMID:
11071577
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center